article thumbnail

Targeting the immunotherapy potential of cytokines IL-12 and IL-18 with new advancements in protein engineering

Drug Target Review

Increasingly, IO researchers and biotech R&D teams are prioritising localised IL-12 delivery mechanisms that target tumours directly. Some approaches have already reached the clinical trial stage, with others not far behind. 2 After activation by an antigen presenting cell, a T helper cell segregates the cytokines.